Data is at the heart of every decision made by CROs, and so can have significant legal and financial implications. In this article ICON experts weigh in on maximising the efficacy of data and ensuring the scientific rigour HTAs expect.

This article is taken from European Pharmaceutical Contractor, August 2022, pages 52-55. © Samedan Ltd

Read article